Literature DB >> 22015675

The management of thrombotic lesions in the cardiac catheterization laboratory.

Fadi Matar1, Jad Mroue.   

Abstract

Plaque rupture with superimposed thrombosis is the major mechanism of acute coronary syndromes. Although angiography underestimates the presence of thrombi, their detection is a poor prognostic indicator which is proportional to their size. Although emergent percutaneous coronary intervention (PCI) in the setting of ST elevation myocardial infarction (STEMI) and early PCI in the setting of unstable angina and non-STEMI were shown to be preferred strategies, the presence of angiographic thrombosis by virtue of causing micro and macro embolization can reduce the benefit of the intervention. Antiplatelet therapy especially using glycoprotein IIb/IIIa inhibitors reduces thrombus size, and improves myocardial perfusion and ventricular function. Routine manual aspiration prior to PCI in STEMI also improves myocardial flow and reduces distal embolization and improves survival. Distal embolic protection devices and mechanical thrombectomy do not have the same clinical benefits however, rheolytic thrombectomy may have a role in large vessels with a large thrombi.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015675     DOI: 10.1007/s12265-011-9327-6

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  86 in total

Review 1.  The search for replacements for unfractionated heparin.

Authors:  E M Antman
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

2.  Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention.

Authors:  J P Collet; G Montalescot; C Lesty; Z Mishal; J Soria; R Choussat; G Drobinski; C Soria; P Pinton; P Barragan; D Thomas
Journal:  Circulation       Date:  2001-05-15       Impact factor: 29.690

3.  The composition of coronary-artery plaques.

Authors:  M J Davies
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

4.  Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.

Authors:  J A de Lemos; E M Antman; C M Gibson; C H McCabe; R P Giugliano; S A Murphy; S A Coulter; K Anderson; J Scherer; M J Frey; R Van Der Wieken; F Van De Werf; E Braunwald
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

5.  Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.

Authors:  L Wallentin; B Lagerqvist; S Husted; F Kontny; E Ståhle; E Swahn
Journal:  Lancet       Date:  2000-07-01       Impact factor: 79.321

Review 6.  Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death.

Authors:  A Farb; A P Burke; A L Tang; T Y Liang; P Mannan; J Smialek; R Virmani
Journal:  Circulation       Date:  1996-04-01       Impact factor: 29.690

7.  Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.

Authors: 
Journal:  Circulation       Date:  1993-01       Impact factor: 29.690

8.  Coronary angioscopy in patients with unstable angina pectoris.

Authors:  C T Sherman; F Litvack; W Grundfest; M Lee; A Hickey; A Chaux; R Kass; C Blanche; J Matloff; L Morgenstern
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

9.  Intracoronary thrombus in syndromes of unstable myocardial ischemia.

Authors:  G W Vetrovec; M J Cowley; H Overton; D W Richardson
Journal:  Am Heart J       Date:  1981-12       Impact factor: 4.749

10.  Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial.

Authors:  Henning Kelbaek; Christian J Terkelsen; Steffen Helqvist; Jens F Lassen; Peter Clemmensen; Lene Kløvgaard; Anne Kaltoft; Thomas Engstrøm; Hans E Bøtker; Kari Saunamäki; Lars R Krusell; Erik Jørgensen; Hans-Henrik T Hansen; Evald H Christiansen; Jan Ravkilde; Lars Køber; Klaus F Kofoed; Leif Thuesen
Journal:  J Am Coll Cardiol       Date:  2008-03-04       Impact factor: 24.094

View more
  2 in total

Review 1.  Embolic protection devices in saphenous vein graft and native vessel percutaneous intervention: a review.

Authors:  Eron Sturm; David Goldberg; Sheldon Goldberg
Journal:  Curr Cardiol Rev       Date:  2012-08

2.  Pre-conditioning with synthetic CpG-oligonucleotides attenuates myocardial ischemia/reperfusion injury via IL-10 up-regulation.

Authors:  P Markowski; O Boehm; L Goelz; A L Haesner; H Ehrentraut; K Bauerfeld; N Tran; K Zacharowski; C Weisheit; P Langhoff; M Schwederski; T Hilbert; S Klaschik; A Hoeft; G Baumgarten; R Meyer; P Knuefermann
Journal:  Basic Res Cardiol       Date:  2013-08-09       Impact factor: 17.165

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.